Synaptogenix Stock Analysis

SNPX -  USA Stock  

USD 7.96  0.27  3.28%

The current slide in stock price created some momentum for investors as it was traded today as low as 7.96 and as high as 8.6 per share. The company directors and management have failed to build on market volatilities in December. However, diversifying your overall positions with Synaptogenix may protect your principal portfolio during upcoming market swings. The stock standard deviation of daily returns for 90 days investing horizon is currently 3.37. The above-average risk is mostly attributed to market volatility and speculations regarding some of the upcoming earning calls from Synaptogenix partners.
Additionally, take a look at World Market Map.

Synaptogenix Stock Analysis 

The Synaptogenix stock analysis report makes it easy to digest most publicly released information about Synaptogenix and get updates on important government artifacts, including earning estimates, SEC corporate filings, and announcements. Synaptogenix Stock analysis module also helps to analyze the Synaptogenix price relationship with some important fundamental indicators such as market cap and management efficiency.

Synaptogenix Stock Analysis Notes

About 24.0% of the company outstanding shares are owned by corporate insiders. The company has price-to-book ratio of 1.75. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Synaptogenix recorded a loss per share of 3.65. The entity had not issued any dividends in recent years. It focuses on developing a product platform based upon a drug candidate called bryostatin for the treatment of Alzheimers disease. The company was incorporated in 2012 and is based in New York, New York. Synaptogenix operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 4 people. To find out more about Synaptogenix contact the company at 973 242 0005 or learn more at

Synaptogenix Investment Alerts

Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Synaptogenix's investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Synaptogenix or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
Synaptogenix generated a negative expected return over the last 90 days
Synaptogenix has high historical volatility and very poor performance
Synaptogenix has high likelihood to experience some financial distress in the next 2 years
Net Loss for the year was (13.77 M).
Synaptogenix currently holds about 31.29 M in cash with (7.87 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.69.
Roughly 24.0% of the company outstanding shares are owned by corporate insiders

Synaptogenix Stock Institutional Investors

Have you ever been surprised when a price of an equity instrument such as Synaptogenix is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Synaptogenix backward and forwards among themselves. Synaptogenix's institutional investor refers to the entity that pools money to purchase Synaptogenix's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Security TypeSharesValue
Ikarian Capital LlcCommon Shares245.6 K2.4 M
Cannell CoCommon Shares76.4 K759 K
Diametric Capital LpCommon Shares36.9 K367 K
Platform Technology PartnersCommon Shares32.5 K323 K
Boothbay Fund Management LlcCommon Shares24.7 K245 K
Prelude Capital Management LlcCommon Shares22.5 K223 K
Renaissance Technologies LlcCommon Shares21.4 K213 K
Note, although Synaptogenix's institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Synaptogenix Market Capitalization

The company currently falls under 'Micro-Cap' category with current market capitalization of 59.8 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Synaptogenix's market, we take the total number of its shares issued and multiply it by Synaptogenix's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities.

Management Efficiency

The entity has return on total asset (ROA) of (23.05) % which means that it has lost $23.05 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (38.31) %, meaning that it created substantial loss on money invested by shareholders. Synaptogenix management efficiency ratios could be used to measure how well synaptogenix manages its routine affairs as well as how well it operates its assets and liabilities.

Technical Drivers

As of the 21st of January, Synaptogenix has the coefficient of variation of (855.36), and Risk Adjusted Performance of (0.09). In relation to fundamental indicators, the technical analysis model makes it possible for you to check existing technical drivers of Synaptogenix, as well as the relationship between them. In other words, you can use this information to find out if the company will indeed mirror its model of past prices and volume data, or the prices will eventually revert. We were able to interpolate data for nineteen technical drivers for Synaptogenix, which can be compared to its competition. Please validate Synaptogenix variance and potential upside to decide if Synaptogenix is priced more or less accurately, providing market reflects its prevalent price of 7.96 per share. Given that Synaptogenix has jensen alpha of (0.41), we advise you to double-check Synaptogenix's current market performance to make sure the company can sustain itself at a future point.

Synaptogenix Price Movement Analysis

Incorrect Input. Please change your parameters or increase the time horizon required for running this function. The output start index for this execution was zero with a total number of output elements of zero. The Triple Exponential Moving Average (T3) indicator is developed by Tim Tillson as Synaptogenix price series composite of a single exponential moving average, a double exponential moving average and a triple exponential moving average. View also all equity analysis or get more info about triple exponential moving average t3 overlap studies indicator.

Synaptogenix Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Synaptogenix insiders, such as employees or executives, is commonly permitted as long as it does not rely on Synaptogenix's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Synaptogenix insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.

Synaptogenix Predictive Daily Indicators

Synaptogenix intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Synaptogenix stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.

Synaptogenix Forecast Models

Synaptogenix time-series forecasting models is one of many Synaptogenix's stock analysis techniquest aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Synaptogenix's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.

About Synaptogenix Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how Synaptogenix stock is reacting to, or reflecting on a current stock market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Synaptogenix shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas, a specific sector, or an individual stock such as Synaptogenix. By using and applying Synaptogenix Stock analysis, traders can create a robust methodology for identifying Synaptogenix entry and exit points for their positions.
It focuses on developing a product platform based upon a drug candidate called bryostatin for the treatment of Alzheimers disease. The company was incorporated in 2012 and is based in New York, New York. Synaptogenix operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 4 people.

Be your own money manager

As an investor, your ultimate goal is to build wealth. Optimizing your investment portfolio is an essential element in this goal. Using our stock analysis tools, you can find out how much better you can do when adding Synaptogenix to your portfolios without increasing risk or reducing expected return.

Did you try this?

Run Portfolio Backtesting Now


Portfolio Backtesting

Avoid under-diversification and over-optimization by backtesting your portfolios
All  Next Launch Module
Additionally, take a look at World Market Map. Note that the Synaptogenix information on this page should be used as a complementary analysis to other Synaptogenix's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Portfolio Comparator module to compare the composition, asset allocations and performance of any two portfolios in your account.

Complementary Tools for Synaptogenix Stock analysis

When running Synaptogenix price analysis, check to measure Synaptogenix's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Synaptogenix is operating at the current time. Most of Synaptogenix's value examination focuses on studying past and present price action to predict the probability of Synaptogenix's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Synaptogenix's price. Additionally, you may evaluate how the addition of Synaptogenix to your portfolios can decrease your overall portfolio volatility.
Price Exposure Probability
Analyze equity upside and downside potential for a given time horizon across multiple markets
Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk
Portfolio Optimization
Compute new portfolio that will generate highest expected return given your specified tolerance for risk
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
Is Synaptogenix's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Synaptogenix. If investors know Synaptogenix will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Synaptogenix listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Synaptogenix is measured differently than its book value, which is the value of Synaptogenix that is recorded on the company's balance sheet. Investors also form their own opinion of Synaptogenix's value that differs from its market value or its book value, called intrinsic value, which is Synaptogenix's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Synaptogenix's market value can be influenced by many factors that don't directly affect Synaptogenix's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Synaptogenix's value and its price as these two are different measures arrived at by different means. Investors typically determine Synaptogenix value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Synaptogenix's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.